1
|
Kubatka P, Kello M, Kajo K, Kruzliak P, Výbohová D, Šmejkal K, Maršík P, Zulli A, Gönciová G, Mojžiš J, Kapinová A, Murin R, Péč M, Adamkov M, Przygodzki RM. Young Barley Indicates Antitumor Effects in Experimental Breast Cancer In Vivo and In Vitro. Nutr Cancer 2016; 68:611-21. [PMID: 27042893 DOI: 10.1080/01635581.2016.1154577] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
The effect of dietary administered young barley containing a mixture of phytochemicals to female rats for the prevention of N-methyl-N-nitrosourea-induced mammary carcinogenesis was evaluated. After carcinogen administration (14 wk), mammary tumors were removed and prepared for histopathological and immunohistochemical analysis. Moreover, in vitro evaluation of possible mechanisms in MCF-7 breast cancer cell line was performed. Barley (0.3%) demonstrated mild antitumor effect in mammary carcinogenesis, yet 3% barley did not further improve this effect. Immunohistochemical analysis of rat tumor cells in treated groups showed significant increase in caspase-3 expression and significant reduction in Ki67 expression. In addition, 3% barley significantly decreased dityrosine levels versus control. Barley in higher dose significantly decreased serum low-density lipoprotein-cholesterol in rats. In vitro studies showed that barley significantly decreased survival of MCF-7 cells in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and significantly decreased 5-bromo-20-deoxyuridine incorporation versus control. Barley prevented cell cycle progression and extended incubation with barley showed significant increase in the percentage of annexin V/propidium iodide-positive MCF-7 cells. Our results propose an antitumor effect for the mixture of phytochemicals present in young barley in a breast cancer model.
Collapse
Affiliation(s)
- Peter Kubatka
- a Department of Medical Biology , Jessenius Faculty of Medicine, Comenius University in Bratislava , Martin , Slovakia
| | - Martin Kello
- b Department of Pharmacology , Faculty of Medicine, P. J. Šafárik University , Košice , Slovakia
| | - Karol Kajo
- c Department of Pathology , Slovak Medical University and St. Elisabeth Oncology Institute , Bratislava
| | - Peter Kruzliak
- d Laboratory of Structural Biology and Proteomics, Central Laboratories, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences , Brno , Czech Republic
| | - Desanka Výbohová
- e Department of Anatomy , Jessenius Faculty of Medicine, Comenius University in Bratislava , Martin , Slovakia
| | - Karel Šmejkal
- f Department of Natural Drugs, Department of Molecular Biology and Pharmaceutical Biotechnology , Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno , Czech Republic
| | - Petr Maršík
- g Department of Quality of Agricultural Products , Faculty of Agrobiology, Food and Natural Resources, Czech University of Life Sciences Prague , Prague , Czech Republic.,h Institute of Experimental Botany AS CR, v. v. i. , Prague , Czech Republic
| | - Anthony Zulli
- i The Centre for Chronic Disease Prevention & Management (CCDPM), College of Health & Biomedicine, Victoria University , Melbourne , Victoria , Australia
| | - Gabriela Gönciová
- b Department of Pharmacology , Faculty of Medicine, P. J. Šafárik University , Košice , Slovakia
| | - Ján Mojžiš
- b Department of Pharmacology , Faculty of Medicine, P. J. Šafárik University , Košice , Slovakia
| | - Andrea Kapinová
- j Department of Medical Biochemistry , Jessenius Faculty of Medicine, Comenius University in Bratislava , Martin , Slovakia
| | - Radovan Murin
- j Department of Medical Biochemistry , Jessenius Faculty of Medicine, Comenius University in Bratislava , Martin , Slovakia
| | - Martin Péč
- a Department of Medical Biology , Jessenius Faculty of Medicine, Comenius University in Bratislava , Martin , Slovakia
| | - Marián Adamkov
- k Department of Histology and Embryology , Jessenius Faculty of Medicine, Comenius University in Bratislava , Martin , Slovakia
| | | |
Collapse
|
2
|
Wolff MS, Britton JA, Boguski L, Hochman S, Maloney N, Serra N, Liu Z, Berkowitz G, Larson S, Forman J. Environmental exposures and puberty in inner-city girls. ENVIRONMENTAL RESEARCH 2008; 107:393-400. [PMID: 18479682 PMCID: PMC3974622 DOI: 10.1016/j.envres.2008.03.006] [Citation(s) in RCA: 114] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/23/2007] [Revised: 03/13/2008] [Accepted: 03/25/2008] [Indexed: 05/17/2023]
Abstract
BACKGROUND Hormonally active environmental exposures are suspected to alter onset of puberty in girls, but research on this question has been very limited. OBJECTIVE We investigated pubertal status in relation to hormonally active environmental exposures among a multiethnic group of 192 healthy 9-year-old girls residing in New York City. METHODS Information was collected on breast and pubic hair stages, weight and height. Phytoestrogen intake was estimated from a food-frequency questionnaire. Three phytoestrogens and bis-phenolA (BPA) were measured in urine. In a subset, 1,1'-dichloro-2,2'-bis(4-chlorophenyl)ethylene (DDE), polychlorinated biphenyls (PCBs) were measured in blood plasma and lead (Pb) in blood. Associations of exposures with pubertal stages (present=stage 2+ vs absent=stage 1) were examined using t-tests and Poisson multivariate regression to derive prevalence ratios (PR, 95%-confidence limits [CI]). RESULTS Breast development was present in 53% of girls. DDE, Pb, and dietary intakes of phytoestrogens were not significantly associated with breast stage. Urinary phytoestrogen biomarker concentrations were lower among girls with breast development compared with no development. In multivariate models, main effects were strongest for two urinary isoflavones, daidzein (PR 0.89 [0.83-0.96] per ln microg/g creatinine) and genistein (0.94 [0.88-1.01]). Body mass index (BMI) is a hormonally relevant, strong risk factor for breast development. Therefore, BMI-modification of exposure effects was examined, and associations became stronger. Delayed breast development was observed among girls with below-median BMI and third tertile (high exposure) of urinary daidzein (PR 0.46 [0.26-0.78]); a similar effect was seen with genistein, comparing to girls >or= median BMI and lowest two tertiles (combined) of these isoflavones. With urinary enterolactone a phytoestrogen effect was seen only among girls with high BMI, where breast development was delayed among those with high urinary enterolactone (PR 0.55 [0.32-0.96] for the upper tertile vs lower two combined). There was no main effect of PCBs on breast stage, but girls with below-median BMI and >or= median PCB levels had reduced risk for breast development (any vs none) compared with other BMI-PCB groups. No biomarkers were associated with hair development, which was present in 31% of girls. CONCLUSIONS Phytoestrogens and PCBs are environmental exposures that may delay breast development, especially in conjunction with BMI, which governs the endogenous hormonal milieu. Further research to confirm these findings may improve our understanding of the role of early life development in breast cancer risk and other chronic diseases related to obesity.
Collapse
Affiliation(s)
- Mary S Wolff
- Department of Community and Preventive Medicine, Mount Sinai School of Medicine, Box 1057, 1 Gustav L. Levy Place, New York, NY 10029, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|